Zobrazeno 1 - 10
of 18
pro vyhledávání: '"D. Hoppensteadt"'
Publikováno v:
Thrombosis Research. 75:609-616
The effect of tissue factor pathway inhibitor (TFPI) on thrombin and factor Xa generation was studied in an in vitro system using a prothrombin complex concentrate. It was found that TFPI, via the direct inhibition of factor Xa and the tissue factor/
Publikováno v:
International angiology : a journal of the International Union of Angiology. 27(6)
Autor:
M, Clark, D, Hoppensteadt, J, Walenga, L, Myers, J, Cunanan, W, Jeske, C, Adiguzel, O, Iqbal, J, Fareed
Publikováno v:
International angiology : a journal of the International Union of Angiology. 27(5)
Heparin is a widely used anticoagulant which is usually obtained from porcine mucosal tissue. The structure of heparin is comparable to other naturally occurring glycosaminoglycans such as chondroitin sulfate and dermatan sulfate. The commercially av
Autor:
Thyyar M. Ravindranath, M. Florian Kujawski, D. Hoppensteadt, Mahmut Töbü, M. Goto, Mohammed M. Sayeed, Omer Iqbal, Muzaffer Demir, Jawed Fareed, V. Samonte
Publikováno v:
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 10(4)
Burn and septic injuries induce profound changes in coagulation status. This study examined the changes in plasma tissue factor pathway inhibitor (TFPI) and thrombin activatable fibrinolytic inhibitor (TAFI) levels in a rat model of burn and septic i
Publikováno v:
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 6(1)
Publikováno v:
The Canadian journal of cardiology. 14
In addition to their use in postsurgical and medical prophylaxis of deep vein thrombosis (DVT), low molecular weight heparins (LMWHs) are being developed for cardiovascular and cerebrovascular indications. Because of manufacturing differences, each L
Publikováno v:
Seminars in thrombosis and hemostasis. 22
Low molecular weight heparins (LMWHs) are now universally accepted as drugs of choice for post-surgical prophylaxis of DVT. Currently these agents are also being developed for therapeutic and cardiovascular indications. Because of manufacturing diffe
Publikováno v:
Blood coagulationfibrinolysis : an international journal in haemostasis and thrombosis. 4
Clivarin (reviparin-sodium) is a homogeneous low molecular weight heparin (LMWH) as determined by the data obtained in molecular profiling studies. The limited biochemical studies carried out indicate that this LMWH has a specific potency of 124 anti
Publikováno v:
Seminars in thrombosis and hemostasis. 19
1. Clivarin is a homogeneous LMWH as determined by the data obtained in molecular profiling studies. 2. The limited biochemical studies carried out indicated that this LMWH has a specific potency of 124 anti-Xa IU/mg and a weaker APTT activity of app
Autor:
Peter Bacher, D. Welzel, Demetra Callas, Jeanine M. Walenga, O. Iqbal, Jawed Fareed, D. Hoppensteadt
Publikováno v:
Thrombosis research. 66(2-3)
Since the beginning of the clinical use of low molecular weight (LMW) heparins their thrombolytic or profibrinolytic potency has been a matter of controversial discussions. Regarding this problem, the aim of our study was to test a LMW-heparin (Sando